Evaluation of the Prognostic Value of Immature Platelet Fraction

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-04-28

Study Completion Date

2025-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Sepsis is a public health issue responsible for six million deaths worldwide each year. It is one of the leading causes of admission and morbidity and mortality in critical care. Its most severe form, septic shock, is responsible for a picture of multiple organ failure syndrome with a high mortality rate estimated at 38%. It appears important to identify routinely available and low-cost biomarkers to identify patients at risk of adverse outcomes.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Retrospective Review of a Comprehensive Cohort of Septic Shock: Assessment of Critical Determinants of Outcome

NCT01775956

Septic Shock

UNKNOWN

Interest of the Balance of Pro-coagulating and Profibrinolytis Activities of the Microparticles (MP) in the Prognosis of Septic Shock

NCT02062970

the Coagulolytic Balance the Mortality Rate the Performance Used to Evaluate the Principal Objective Are Technical Performances, Sensibility and Specificity of the Tests

UNKNOWN NA

Prognostic Interest of Leucocyte Immunophenotyping During the Acute Phase of Sepsis

NCT01995448

Sepsis With Acute Organ Dysfunction

COMPLETED

Prognostic Value of Complete Blood Count in Severe Infections

NCT03685071

Infection Systemic

UNKNOWN

Prospective Validation of Clini-biological Parameters Including Initial Hemostasis, Which Improve the Prediction of Death at 1 Month Among Patients With Septic Shock

NCT01231672

Shock, Septic

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In the pathophysiology of host defense against infection, coagulation plays a major role. In the most severe forms of sepsis, there is an activation of coagulation, particularly platelets, which can cause an alteration of microcirculation and contribute to organ failure. This mechanism is called thromboinflammation. The appearance of thrombocytopenia in sepsis is a risk factor for severity and intrahospital mortality. Immature (or reticulated) platelets are young platelets that have just been released by the bone marrow. They are more prothrombotic and hyperactive than more mature platelets. They are a good marker of thrombopoiesis and platelet renewal, and can be easily obtained routinely on a complete blood count. Several studies show that the immature platelet count and/or fraction (IPF) could be a useful tool for predicting the development of sepsis and its severity. It appears interesting to study these IPFs in patients with sepsis to identify them and implement more aggressive therapies to prevent adverse outcomes in these patients. To distinguish between sepsis and inflammation and validate this marker, it will be compared to an inflammatory group using patients who underwent cardiopulmonary bypass as part of cardiac surgery.

The main objective of this study is to investigate the potential impact of the immature platelet fraction on the prognosis at day 28 of patients admitted to critical care for sepsis or septic shock.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Septic Shock

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sepsis Group

Patient admitted for sepsis in critical care

No interventions assigned to this group

Inflammatory control group

Patient admitted for an anesthesia consultation for cardiac surgery under extracorporeal circulation

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Any adult patient admitted to critical care for sepsis defined by a SOFA score \> or = 2 or an increase of at least 2 points if there was organ dysfunction pre-existing to the infection.
* For the inflammatory control group, we will include adult patients who have required extracorporeal circulation for more than 1 hour for cardiac surgery.
* Patients who have read and understood the information letter and do not object to participating in the study
* Patients affiliated with a social security scheme

Exclusion Criteria

* Patient refusal
* Pregnant, parturient, or breastfeeding woman
* Person deprived of liberty by an administrative or judicial decision or person placed under judicial protection/guardianship or curatorship
* Person who does not understand or speak French
* Moribund
* Febrile aplasia
* Hematological diseases
* Decompensated cirrhosis
* Ongoing chemotherapy

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No